Johannes Hellmuth

13PUBLICATIONS
113CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markersArtificial life and complex adaptive systems
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Feb 09, 2026
MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay.

Jan-Michel Heger, Julia Mattlener, Helen Kaul

|Jul 17, 2025
Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial.

Justin Ferdinandus, Helen Kaul, Alexander Fosså

|Apr 03, 2025
Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma.

Adrian Gottschlich, Ruth Grünmeier, Gordon Victor Hoffmann

|Nov 03, 2023
Impaired immune responses and prolonged viral replication in lung allograft recipients infected with SARS-CoV-2 in the early phase after transplantation.

Olaf M Glueck, Xiaoling Liang, Irina Badell

|Dec 21, 2022
Statistical biases due to anonymization evaluated in an open clinical dataset from COVID-19 patients.

Carolin E M Koll, Sina M Pütz, Thierry Meurers

|Nov 20, 2022
Distinct and dynamic activation profiles of circulating dendritic cells and monocytes in mild COVID-19 and after yellow fever vaccination.

Elena Winheim, Tabea Eser, Flora Deák

Pageof 3

Frequent Collaborators

5 joint publications

Maximilian Muenchhoff

3 joint publications

Clemens Scherer

2 joint publications

Justin Ferdinandus

2 joint publications

Oliver Weigert